Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas.

Zhang L, Kundu S, Feenstra T, Li X, Jin C, Laaniste L, El Hassan TE, Ohlin KE, Yu D, Olofsson T, Olsson AK, Pontén F, Magnusson PU, Nilsson KF, Essand M, Smits A, Dieterich LC, Dimberg A.

Sci Signal. 2015 Dec 8;8(406):ra125. doi: 10.1126/scisignal.aaa1690.

PMID:
26645582
2.

Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Ohlin KE, Sebastianutto I, Adkins CE, Lundblad C, Lockman PR, Cenci MA.

Neuroimage. 2012 May 15;61(1):228-39. doi: 10.1016/j.neuroimage.2012.02.066. Epub 2012 Mar 3.

3.

Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease.

Cenci MA, Ohlin KE, Odin P.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):670-84. Review.

PMID:
21838677
4.

Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.

Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA.

Brain. 2011 Aug;134(Pt 8):2339-57. doi: 10.1093/brain/awr165. Epub 2011 Jul 19.

5.

Rodent models of treatment-induced motor complications in Parkinson's disease.

Cenci MA, Ohlin KE.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S13-7. doi: 10.1016/S1353-8020(09)70828-4. Review.

PMID:
20123549
6.

Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.

Cenci MA, Ohlin KE, Rylander D.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S59-63. doi: 10.1016/S1353-8020(09)70782-5. Review.

PMID:
20083009
7.

Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.

Lindgren HS, Ohlin KE, Cenci MA.

Neuropsychopharmacology. 2009 Nov;34(12):2477-88. doi: 10.1038/npp.2009.74. Epub 2009 Jul 15.

8.

The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.

Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA.

Behav Brain Res. 2007 Feb 12;177(1):150-9. Epub 2006 Dec 8.

PMID:
17157933

Supplemental Content

Loading ...
Support Center